Heron Therapeutics Company Profile (NASDAQ:HRTX)

About Heron Therapeutics

Heron Therapeutics logoHeron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: HRTX
  • CUSIP:
Key Metrics:
  • Previous Close: $15.75
  • 50 Day Moving Average: $17.33
  • 200 Day Moving Average: $18.59
  • 52-Week Range: $14.75 - $31.32
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.50
  • P/E Growth: -0.03
  • Market Cap: $N/A
  • Beta: 1.26
  • Return on Equity: -127.30%
  • Return on Assets: -105.83%
  • Current Ratio: 2.91%
  • Quick Ratio: 2.79%
Additional Links:
Companies Related to Heron Therapeutics:

Analyst Ratings

Consensus Ratings for Heron Therapeutics (NASDAQ:HRTX) (?)
Ratings Breakdown: 9 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $42.13 (174.43% upside)

Analysts' Ratings History for Heron Therapeutics (NASDAQ:HRTX)
DateFirmActionRatingPrice TargetDetails
10/26/2016AegisInitiated CoverageBuy$41.00View Rating Details
10/8/2016Leerink SwannSet Price TargetBuy$34.00View Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$41.00View Rating Details
10/3/2016Jefferies GroupLower Price TargetBuy$46.00 -> $40.00View Rating Details
9/9/2016JMP SecuritiesReiterated RatingBuyView Rating Details
9/6/2016Lake Street CapitalReiterated RatingBuy$45.00View Rating Details
8/9/2016Cantor FitzgeraldReiterated RatingBuy$38.00View Rating Details
7/9/2016Cowen and CompanyReiterated RatingBuyView Rating Details
4/20/2016Noble FinancialReiterated RatingBuy$51.00View Rating Details
9/24/2015Bank of America Corp.Boost Price TargetBuy$54.00View Rating Details
(Data available from 10/28/2014 forward)


Earnings History for Heron Therapeutics (NASDAQ:HRTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2016Q2($0.96)($1.17)ViewN/AView Earnings Details
5/5/2016Q1($0.92)($0.92)ViewN/AView Earnings Details
2/19/2016Q4($0.64)($0.87)ViewN/AView Earnings Details
11/6/2015Q3($0.67)($0.63)ViewN/AView Earnings Details
8/7/2015($0.65)($0.74)ViewN/AView Earnings Details
5/8/2015Q115($0.68)($0.70)ViewN/AView Earnings Details
3/13/2015($0.79)($0.71)ViewN/AView Earnings Details
11/6/2014($0.69)($0.66)ViewN/AView Earnings Details
8/4/2014($0.62)($0.78)ViewN/AView Earnings Details
5/8/2014($0.67)($0.74)ViewN/AView Earnings Details
3/5/2014($0.53)($0.75)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Heron Therapeutics (NASDAQ:HRTX)
Current Year EPS Consensus Estimate: $-4.31 EPS
Next Year EPS Consensus Estimate: $-2.79 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($1.21)($0.90)($1.06)
Q2 20163($0.98)($0.92)($0.95)
Q3 20163($1.19)($1.01)($1.09)
Q4 20163($1.20)($0.86)($0.99)
Q1 20171($0.77)($0.77)($0.77)
Q2 20171($0.79)($0.79)($0.79)
Q3 20171($0.60)($0.60)($0.60)
Q4 20171($0.15)($0.15)($0.15)
(Data provided by Zacks Investment Research)


Dividend History for Heron Therapeutics (NASDAQ:HRTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Heron Therapeutics (NASDAQ:HRTX)
Insider Ownership Percentage: 20.31%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/10/2016Robert RosenInsiderSell100,000$23.30$2,330,000.00View SEC Filing  
4/21/2016Robert RosenPresidentSell200,000$23.23$4,646,000.00View SEC Filing  
6/10/2015Kevin C TangDirectorBuy121,212$24.75$2,999,997.00View SEC Filing  
6/2/2015Kevin C TangDirectorBuy150,000$20.62$3,093,000.00View SEC Filing  
6/1/2015Kimberly ManhardDirectorSell2,708$21.17$57,328.36View SEC Filing  
6/25/2014Barry D QuartCEOBuy10,000$11.75$117,500.00View SEC Filing  
6/25/2014Kevin C TangDirectorBuy510,638$11.75$5,999,996.50View SEC Filing  
11/20/2013Barry D QuartCEOBuy1,000,000$0.40$400,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Heron Therapeutics (NASDAQ:HRTX)
finance.yahoo.com logoCoverage initiated on Heron Therapeutics by Aegis Capital (NASDAQ:HRTX)
finance.yahoo.com - October 26 at 5:33 PM
News IconInsiders Pruning Their Holdings in Heron Therapeutics, Inc ... - CSZ News (NASDAQ:HRTX)
cincysportszone.com - October 26 at 8:40 AM
News IconRating Sentiment Coverage: How Many Heron Therapeutics Inc (NASDAQ:HRTX)'s Analysts Are Bullish? - MoneyMakingArticles (NASDAQ:HRTX)
www.mmahotstuff.com - October 26 at 8:40 AM
4-traders.com logoHeron Therapeutics Inc (NASDAQ:HRTX) Files An 8-K (NASDAQ:HRTX)
www.4-traders.com - October 21 at 5:34 PM
News IconFilings Worth Watching: Tang Capital Management LLC Has Lifted Holding in Heron Therapeutics INC (HRTX) as ... - Chester News (NASDAQ:HRTX)
www.chesterindependent.com - October 21 at 5:34 PM
News IconLatest Analyst Ratings For Heron Therapeutics Inc (HRTX) - The De Soto Edge (NASDAQ:HRTX)
www.desotoedge.com - October 21 at 8:40 AM
News IconNotable Thursday Option Activity: DISH, HRTX, STAR (NASDAQ:HRTX)
www.stockoptionschannel.com - October 20 at 5:31 PM
News IconShare Value Diminishing Over Past Month: Heron Therapeutics, Inc. (NASDAQ:HRTX) - CSZ News (NASDAQ:HRTX)
cincysportszone.com - October 16 at 5:21 PM
News IconSell-side is Weighing in on Heron Therapeutics, Inc. (NASDAQ:HRTX) Earnings - CSZ News (NASDAQ:HRTX)
cincysportszone.com - October 14 at 5:22 PM
realistinvestor.com logoHeron Therapeutics, Inc. (NASDAQ:HRTX) EPS Target Range From $-4.08 To $-3.43 - RealistInvestor.com (NASDAQ:HRTX)
www.realistinvestor.com - October 12 at 5:30 PM
News IconStock Perspective: Heron Therapeutics, Inc. (NASDAQ:HRTX) Earnings in View - CSZ News (NASDAQ:HRTX)
cincysportszone.com - October 9 at 9:55 AM
News IconAnalyst Target Review on Heron Therapeutics, Inc. (NASDAQ:HRTX) - Recall News (NASDAQ:HRTX)
www.automobile-recalls.net - October 7 at 5:22 PM
finance.yahoo.com logoBrean Capital Sees A $300 Million Opportunity For Heron Therapeutics New Drug Launch (NASDAQ:HRTX)
finance.yahoo.com - October 4 at 5:19 PM
insidermonkey.com logoHere's Why TASER International, Heron Therapeutics and Three Other Stocks Are Trading Lower on Monday - Insider Monkey (blog) (NASDAQ:HRTX)
www.insidermonkey.com - October 4 at 10:14 AM
schaeffersresearch.com logoAnalyst Update: Heron Therapeutics Inc, Fred's, Inc., and Cognizant Technology Solutions Corp - Schaeffers Research (blog) (NASDAQ:HRTX)
www.schaeffersresearch.com - October 4 at 10:14 AM
nasdaq.com logoOversold Conditions For Heron Therapeutics - Nasdaq (NASDAQ:HRTX)
www.nasdaq.com - October 4 at 10:14 AM
nasdaq.com logoOversold Conditions For Heron Therapeutics (NASDAQ:HRTX)
www.nasdaq.com - October 3 at 5:12 PM
News IconHeron Therapeutics Resubmits SUSTOL® New Drug Application to FDA (NASDAQ:HRTX)
investorsbuz.com - October 3 at 10:05 AM
News IconAnalyst Coverage: Heron Therapeutics Inc (HRTX) - NewsDen - NewsDen (NASDAQ:HRTX)
newsden.net - October 2 at 4:52 PM
biz.yahoo.com logoHERON THERAPEUTICS, INC. /DE/ Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:HRTX)
biz.yahoo.com - September 30 at 5:46 PM
News IconLatest Analyst Reports On Heron Therapeutics Inc - NewsDen (NASDAQ:HRTX)
newsden.net - September 30 at 10:38 AM
News IconBroker Roundup For Heron Therapeutics Inc (HRTX) - The De Soto Edge (NASDAQ:HRTX)
desotoedge.com - September 30 at 10:38 AM
investornewswire.com logoCan Shares Of Heron Therapeutics, Inc. (NASDAQ:HRTX) Hit $55? - Investor Newswire (NASDAQ:HRTX)
www.investornewswire.com - September 28 at 10:22 AM
News IconWhat is the Sell-side Saying About Heron Therapeutics, Inc. (NASDAQ:HRTX)? - Frisco Fastball (NASDAQ:HRTX)
friscofastball.com - September 22 at 8:36 AM
investornewswire.com logoShares Of Heron Therapeutics, Inc. (NASDAQ:HRTX) Expected To Hit $55 - Investor Newswire (NASDAQ:HRTX)
www.investornewswire.com - September 21 at 9:41 AM
News IconSell-side Consensus Sees Heron Therapeutics, Inc. (NASDAQ:HRTX) Going Where Near-Term? - Frisco Fastball (NASDAQ:HRTX)
friscofastball.com - September 15 at 8:36 AM
capitalcube.com logoHeron Therapeutics, Inc. :HRTX-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016 (NASDAQ:HRTX)
www.capitalcube.com - September 14 at 9:44 AM
News IconHeron Therapeutics Inc. (NASDAQ: HRTX) Buy Rating Reiterated at JMP Securities - BNB Daily (blog) (NASDAQ:HRTX)
www.baseball-news-blog.com - September 13 at 10:16 AM
News IconShares Lower Over the Past Quarter: Heron Therapeutics, Inc. (NASDAQ:HRTX) - Post News (NASDAQ:HRTX)
www.kentuckypostnews.com - September 11 at 9:49 AM
smarteranalyst.com logoCompany Update (NASDAQ:HRTX): Heron Therapeutics Inc Announces Presentations of Results from Phase 2 ... - Smarter Analyst (NASDAQ:HRTX)
www.smarteranalyst.com - September 9 at 10:11 AM
streetinsider.com logoHeron Therapeutics (HRTX) to Present Statistically Significant HTX-011 Phase 2 Data at PAINWeek - StreetInsider.com (NASDAQ:HRTX)
www.streetinsider.com - September 8 at 9:23 AM
finance.yahoo.com logoHeron Therapeutics Announces Presentations of Results from Phase 2 Clinical Trial of HTX-011 in Hernia Repair at PAINWeek® 2016 (NASDAQ:HRTX)
finance.yahoo.com - September 8 at 9:23 AM
benzinga.com logoFDA Approval Of Heron Therapeutics' Lead Product Has Lake Street Recommending A Buy (NASDAQ:HRTX)
www.benzinga.com - September 6 at 5:30 PM
News IconStock Struggling for the Quarter: Heron Therapeutics, Inc. (NASDAQ ... - Post News (NASDAQ:HRTX)
www.kentuckypostnews.com - September 4 at 9:48 AM
News IconHeron Therapeutics Announces Poster Presentations of Data from Phase 2 Clinical Program for HTX-011 at PAINWeek® 2016 (NASDAQ:HRTX)
ih.advfn.com - August 29 at 10:01 AM
streetinsider.com logoHeron Therapeutics (HRTX) Presents Positive Data from HTX-011 Phase 2 in Hernia Repair (NASDAQ:HRTX)
www.streetinsider.com - August 29 at 10:01 AM
News IconHeron Therapeutics Inc. (NASDAQ: HRTX) Outperform Rating Reiterated at Leerink Swann - BNB Daily (blog) (NASDAQ:HRTX)
www.baseball-news-blog.com - August 19 at 5:28 PM
finance.yahoo.com logoHERON THERAPEUTICS, INC. /DE/ Financials (NASDAQ:HRTX)
finance.yahoo.com - August 17 at 5:44 PM
investornewswire.com logoWill Heron Therapeutics, Inc. (NASDAQ:HRTX) Hit $55 Price Target? - Investor Newswire (NASDAQ:HRTX)
www.investornewswire.com - August 17 at 8:33 AM
finance.yahoo.com logoBeyond SUSTOL: Why Heron (HRTX) is a Great Biotech Stock to Buy (NASDAQ:HRTX)
finance.yahoo.com - August 15 at 5:45 PM
thestreet.com logoBiotech Stock Mailbag: Heron, Acadia, Exact Sciences, Sarepta (NASDAQ:HRTX)
www.thestreet.com - August 12 at 8:37 AM
News IconHeron’s (HRTX) Sustol For Chemotherapy-Induced Nausea Approved By FDA In Third Attempt (NASDAQ:HRTX)
www.ibtimes.com - August 11 at 8:31 AM
finance.yahoo.com logoBulls target upside in Heron Therapeutics (NASDAQ:HRTX)
finance.yahoo.com - August 11 at 8:31 AM
marketwatch.com logoHeron Therapeutics shares rise 18% in pre-market trade after company said treatment was approved by FDA - MarketWatch (NASDAQ:HRTX)
www.marketwatch.com - August 10 at 5:47 PM
schaeffersresearch.com logoFDA Nod Sets Heron Therapeutics Inc (HRTX) Options on Fire - Schaeffers Research (blog) (NASDAQ:HRTX)
www.schaeffersresearch.com - August 10 at 5:47 PM
biz.yahoo.com logoHERON THERAPEUTICS, INC. /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fi (NASDAQ:HRTX)
biz.yahoo.com - August 10 at 5:47 PM
investors.com logoHeron Therapeutics receives FDA approval for anti-nausea drug (NASDAQ:HRTX)
www.proactiveinvestors.com - August 10 at 12:28 PM
forbes.com logoNoteworthy Wednesday Option Activity: GD, HRTX, LMT (NASDAQ:HRTX)
www.forbes.com - August 10 at 12:28 PM
marketwatch.com logoHeron Therapeutics shares halted before company said treatment approved by FDA (NASDAQ:HRTX)
www.marketwatch.com - August 10 at 12:28 PM
streetinsider.com logoHeron Therapeutics (HRTX) Reports FDA Approval of SUSTOL (NASDAQ:HRTX)
www.streetinsider.com - August 10 at 12:28 PM


Heron Therapeutics (NASDAQ:HRTX) Chart for Friday, October, 28, 2016

Last Updated on 10/28/2016 by MarketBeat.com Staff